Eidos Therapeutics has received a non-binding proposal dated August 8, 2019 (the Proposal) from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder (BridgeBio), to purchase all of the outstanding common stock of the Company not already owned by BridgeBio.
Boehringer Ingelheim has forged a multi-year partnership with The University of Texas MD Anderson Cancer Center to carry out joint research towards rapid advancement of new therapies for various forms of cancers.
Jazz Pharmaceuticals has acquired US-based clinical-stage biotechnology company Cavion for a total potential consideration of $312.5m (£258.9m).
Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today the opening of its Clinical Development Shanghai Center, signalling the further expansion of R&D capability, especially in Oncology and Non-alcoholic steatohepatitis (NASH).
Bayer has agreed to acquire the remaining 50.2% interest in US-based biotechnology company BlueRock Therapeutics for around $240m (£197m) in cash.
Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagent.
An affiliate of investment firm Permira has agreed to acquire small molecule company Cambrex in a deal valued at around $2.4bn (£1.97bn), including its net debt.
GSK has granted exclusive technology license for its clinical-stage Ebola vaccines to the Sabin Vaccine Institute, a US-based nonprofit organisation that promotes global vaccine development.
Aquinox Pharmaceuticals has signed an agreement to acquire biopharmaceutical company Neoleukin Therapeutics.
Biotechnology company Antikor Biopharma Ltd is pleased to announce that it has entered into an Investment Agreement for up to US$3,100,000 with Essex Bio-Investment, a wholly-owned subsidiary of Essex Bio-Technology Ltd (”EssexBio”), which will enable Antikor to consolidate and expand its position as a leading innovator in smaller-format conjugate therapies for solid tumours.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.